Tandem Diabetes Care Files 8-K on Financing and Equity

TL;DR

Tandem Diabetes Care just filed an 8-K detailing financing agreements and equity sales. Watch for more details.

AI Summary

On March 4, 2024, Tandem Diabetes Care, Inc. entered into a Material Definitive Agreement related to its financing. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities. Specific details regarding the dollar amounts and terms of these agreements were not fully disclosed in this initial filing.

Why It Matters

This filing indicates significant financial activities for Tandem Diabetes Care, potentially impacting its capital structure and shareholder equity.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and financial obligations, which inherently carry financial risks.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• March 4, 2024 (date) — Date of earliest event reported
• 001-36189 (other) — SEC File Number
• 20-4327508 (other) — I.R.S. Employer Identification No.
• 12400 High Bluff Drive (address) — Principal executive office address
• San Diego (location) — City of principal executive office
• California (location) — State of principal executive office
• 92130 (zip_code) — Zip code of principal executive office

FAQ

From the Filing

0001438133-24-000042.txt : 20240311 0001438133-24-000042.hdr.sgml : 20240311 20240308181950 ACCESSION NUMBER: 0001438133-24-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20240304 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 24736042 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20240304.htm 8-K tndm-20240304 0001438133 FALSE 0001438133 2024-03-04 2024-03-04   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 1.01 Entry into a Material Agreement. Indenture and Notes On March 8, 2024, Tandem Diabetes Care, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $316.25 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “Notes&#822